Checkpoint Inhibitor Refractory Cancer (PD-L1 and PD-1) Market Research Report 2024-2030: Biomarker Testing Revolutionizes Treatment, Personalized Medicine and Immunotherapy Bolster Growth
October 23, 2024 06:33 ET
|
Research and Markets
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Global Checkpoint Inhibitor Refractory Cancer Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Application, End-User,...
Gastric Cancer Market Research Report 2024-2030 by Immunotherapy, Chemotherapy, Radiation Therapy, Surgery, Target Therapies, PD-1/PD-L1 Inhibitors, HER2 Antagonists VEGFR2 Antagonists
September 11, 2024 11:03 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "Global Gastric Cancer Market (2024 Edition): Analysis By Indication (Gastric Cancer/Gastroesophageal Junction Cancer, Gastrointestinal Stromal...
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors - Global Strategic Business Report 2024-2030, with Coverage of Akeso, Alphamab Oncology, BioAtla, BioNTech, Sino Biological and Xencor
September 04, 2024 09:41 ET
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors - Global Strategic Business Report" has been added to ResearchAndMarkets.com's...
Global Immune Checkpoint Inhibitors Market Analysis Report 2024-2030: Growing FDA Approvals of Immune Checkpoint Inhibitors and Increasing Funding for Advancing Cancer Immunotherapy
June 24, 2024 10:26 ET
|
Research and Markets
Dublin, June 24, 2024 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report by Type (PD-1, PD-L1, CTLA-4), Application (Lung Cancer, Breast...
Anti-CD279 (PD-1) Antibody Drug Pipeline Research Report 2024: Insights on 40+ Companies Featuring GlaxoSmithKline, Innovent Biologics, BeiGene, and Shanghai Junshi Biosciences
April 11, 2024 09:15 ET
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Anti-CD279 (PD-1)...
$2+ Bn PD-1 Resistant Head and Neck Cancer Markets - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2022 and 2023-2028F
February 12, 2024 04:14 ET
|
Research and Markets
Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ...
Global PD-1/PDL-1 Inhibitor Market Report 2022: Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens Fueling Sector
September 21, 2022 07:53 ET
|
Research and Markets
Dublin, Sept. 21, 2022 (GLOBE NEWSWIRE) -- The "PD-1/PDL-1 Inhibitor Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032" report...
PD-1 Resistant Head and Neck Cancer (HNC) Market Landscape Report 2021
August 31, 2021 04:08 ET
|
Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's...